Tivic Health Systems

Tivic Health Systems, Inc. is a publicly traded commercial-stage health technology company focused on advancing the field of bioelectronic medicine. Founded in 2016 by Jennifer Ernst and biomedical engineer John Claude, the company aims to provide non-invasive, drug-free solutions for inflammatory conditions. Ernst, the CEO, brought her extensive experience in commercializing new technologies from roles at Xerox PARC and Thin Film Electronics, while Claude, a medical device inventor, identified the potential for a handheld microcurrent device for sinus treatment.

The company's business model is centered on the direct-to-consumer sale of its medical devices through online platforms like its own website, Amazon, Walgreens.com, CVS.com, and BestBuy.com. This strategy targets a mass market of consumers seeking alternatives to pharmaceutical treatments for common ailments. Tivic Health went public with an initial public offering on the Nasdaq Capital Market under the symbol "TIVC" on November 11, 2021, raising gross proceeds of $15 million to fund sales and marketing expansion.

Tivic Health's flagship product is ClearUP, a handheld bioelectronic device for the temporary relief of sinus pain and congestion from conditions like allergies, colds, and flu. The device received FDA clearance in 2019 and was launched commercially the same year. ClearUP utilizes a proprietary microcurrent waveform to stimulate nerve fibers under the skin around the sinus passages, which helps to reduce inflammation and congestion. A key feature is its use of a proprietary algorithm to detect optimal treatment points on the skin, indicated by a vibration, for efficient delivery of the low-level electrical stimulation. A typical five-minute treatment can provide relief for up to six hours without the chemical side effects associated with some medications. The company has secured a robust intellectual property portfolio, with multiple patents in the U.S. and Europe protecting its adaptive microcurrent technology.

Looking forward, Tivic Health is expanding its focus beyond sinus care to become a more diversified therapeutics company. It is actively developing its non-invasive vagus nerve stimulation (ncVNS) platform to address a range of conditions, including anxiety disorders and heart failure, and is exploring other applications for its bioelectronic technology. Keywords: bioelectronic medicine, neurostimulation, non-invasive therapy, direct-to-consumer medtech, sinus relief, allergy treatment, microcurrent technology, neuromodulation, FDA cleared device, consumer health tech, vagus nerve stimulation, John Claude, Jennifer Ernst, ClearUP device, TIVC, inflammatory conditions, drug-free treatment, health technology, chronic condition solutions, trigeminal nerve stimulation